{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022908","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.489398+00:00","generated_at":"2026-05-17T15:12:02.135108+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"confidence":"high","headline":"Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025","bullets":["Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.","HREC approval secured in Australia; Southern Star Research appointed CRO; Sterling Pharma Solutions for cGMP manufacturing.","Phase IIa trial initiation anticipated Q3 2025; IND submission for Phase IIb expected Q3-Q4 2025.","Six months ended June 30, 2025: R&D expenses down 50%, G&A costs down 8%, net losses down 6% YoY.","No FDA-approved pharmacological treatment currently exists for concussion; market opportunity $8.9B by 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022908","json":"https://secwatch.observer/filing/0001641172-25-022908.json","markdown":"https://secwatch.observer/filing/0001641172-25-022908.md","text":"https://secwatch.observer/filing/0001641172-25-022908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000164117225022908/0001641172-25-022908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000164117225022908/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:12:02.135108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}